Since 2000, the annual Work Plan of the Office of the Inspector General (OIG) listed clinical research and clinical trials as a compliance target. As a result, sponsors, investigators, and institutions have increased their vigilance over the operation of clinical research activities. Have those efforts been in the right direction? Have they been enough?
This session will focus on learning the perspective, understanding the actions, and preparing to respond to the OIG’s position and priorities.
Presenters
- William Moran is the recently retired regional inspector general for the U.S. Department of Health & Human Services, Region V. Mr. Moran currently is a vice president with the Chicago office of Strategic Management Systems, Inc.
- LaDale K. George is a partner with Foley’s Health Care Industry Team and is the leader of the Translational Research Focus Group.
Related Insights
March 12, 2026
Foley Viewpoints
What To Do If You Receive an NAIC AI Systems Evaluation Tool Pilot Request
Summary & Takeaways: The NAIC’s AI Systems Evaluation Tool Pilot Project has begun generating domiciliary regulator requests for…
March 12, 2026
Health Care Law Today
GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters
On March 3, 2026, U.S. Food & Drug Administration (FDA) sent 30 warning letters to telehealth companies that market compounded GLP‑1…
March 26, 2026
Events
KASBP Boston 2025-26 Dinner & Learn Series
Foley & Lardner attorneys will be featured as presenters during the Korean American Society in Biotech and Pharmaceuticals (KASBP) Boston 2025-26 Dinner & Learn Series event titled “IP & FDA Regulatory Strategy in the AI Era.”